Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.
ConditionMelanoma of Skin
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-39
SponsorEnte Ospedaliero Ospedali Galliera
About this trial
The primary objective of the study is to analyse a local cohort of patients aged 18-39 years with melanoma diagnosis in order to determine the prevalence of the disease in this age group.
Secondary objectives are the following:
* To identify risk factors associated with melanoma in young people. * To characterise the phenotype and dermoscopic features of melanoma in patients aged 18-39 years. * To analyse the relationship between the clinical and histopathological features of melanoma in young people. * To identify the mutational status of B-RAF in the sample of patients analysed.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
written informed consent
age > 18 years and < 40 years
diagnosis of cutaneous melanoma even non-primary
Disqualifiers
None
Trial population
Since there are no epidemiological data about the prevalence of melanoma in subjects aged 18-39 years, there are very few data available on risk factors in this age group and the impact of the disease. The present study, therefore, will enroll about 25 patients who will attend the Dermatology Unit and who have a histological diagnosis of cutaneous melanoma in a period of 24 months of observation.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
25 Participants
are grouped into 1 trial groupGroup A: ARM 1
Trial outcomes
Primary outcomes
1
Melanoma prevalence
Estimated prevalence of melanoma in a cohort group of patients aged 18 - 39 years
Time frame
3 yearsSecondary outcomes
1
Risk factor
Identification of risk factors associated with melanoma in young people.
Time frame
3 years2
Melanoma phenotype
Description of the main phenotypic of melanoma in this age group.
Time frame
3 years3
Histopathological feature
Evaluation of the likely association between clinical and histopathological features of melanoma in young people.
Time frame
3 years4
Mutational status
Identification of the presence of B-RAF mutations
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov